Q-omics provides the consensus-scored MICOS10-NBL1 profile across patient tissues and cancer cell-line models. MICOS10-NBL1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MICOS10-NBL1 is differentially expressed in 8, with the highest sampling consensus in KIRP. Additionally, MICOS10-NBL1 RNA expression shows 9,282 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KIRP, and UVM as cancer lineages where MICOS10-NBL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MICOS10-NBL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MICOS10-NBL1 survival associations across molecular data types. MICOS10-NBL1 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MICOS10-NBL1 RNA expression–survival associations across cancer types. High MICOS10-NBL1 expression shows unfavorable associations in KIRC, STAD, BRCA, ACC and LIHC, but favorable associations in ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for MICOS10-NBL1 RNA expression.
This table summarizes MICOS10-NBL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for MICOS10-NBL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MICOS10-NBL1 shows lower tumor expression in KICH and higher tumor expression in KIRP, LIHC, HNSC, STAD and ESCA. The KIRP box plot shows higher MICOS10-NBL1 RNA expression in tumor versus normal tissue (log2 FC = +0.040, t-test p = .004).
This table shows molecular features associated with MICOS10-NBL1 in patient tissues and cancer cell lines. In patient samples, MICOS10-NBL1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
